Although the company obviously didn’t make any mention of it, the timing of the new feature is somewhat ironic, arriving ...
Among the highlights of WCLC are final overall survival (OS) data from AstraZeneca's FLAURA 2 study of EGFR inhibitor Tagrisso (osimertinib) given in combination with chemotherapy as a first-line ...